📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. (2020)

First Author: Rossignol P

Attributed to: The Evaluation of blood pressure treatment stratified according to Central Aortic Systolic Pressure (CASP) in Young Hypertensive Patients - The TREAT CASP study funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/ejhf.1860

PubMed Identifier: 32452085

Publication URI: http://europepmc.org/abstract/MED/32452085

Type: Journal Article/Review

Volume: 22

Parent Publication: European journal of heart failure

Issue: 8

ISSN: 1388-9842